Health Canada has approved Alemtuzumab. Alemtuzumab will be marketed by Genzyme as Lemtrada for the treatment of relapsing remitting multiple sclerosis (RRMS), with active disease, who have not shown an adequate response to interferon beta or other disease-modifying therapies. Alemtuzumab is a monoclonal antibody which targets the CD52 protein. The drug was used for several[…]
Health Canada Approves Alemtuzumab for RRMS Patients
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Health Canada Approved 2013, Monoclonal Antibodies / mAb Tags: Alemtuzumabglatiramer acetateLemtradaleukemiarelapsing remitting multiple sclerosisRRMS Dec 13, 2013
FDA Approves Twice a Day Dose of Dimethyl Fumarate for MS
Immunosuppressant Tags: glatiramer acetateMSmultiple sclerosis Apr 15, 2013
The recent approval of dimethyl fumarate CAS# 624-49-7, on March 27th, 2013, was an encouraging sign for the 2.5 million patients worldwide who are suffering with Multiple Sclerosis. The FDA approved Tecfidera, the brand name for dimethyl fumarate, which is developed by Biogen. As easy to dispense oral capsules, this new treatment for MS is[…]
Shocking Diagnosis of Reality Star Creates a Whirlwind of Attention for Glatiramer Acetate
Drug Research & Development API, Immunological Agent, Patent Expiration 2014 Tags: dexamethasoneglatiramer acetateMSmultiple sclerosis Jun 22, 2012
Glatiramer, CAS# 28704-27-0, and Glatiramer Acetate, CAS# 147245-92-9, are also known as Copaxone. In the spotlight recently, Copaxone’s patent is due to expire on May 24, 2014. The flurry of interest regarding Copaxone follows the devastating diagnosis of Multiple Sclerosis for beloved reality star Jack Osbourne. In mid June of 2012 reports surfaced about Jack’s[…]